Abstract
Background Three-dimensional motion analysis represents a quantitative and objective approach to assess spatio-temporal and kinematic changes in Parkinson’s disease (PD). However, these parameters, focusing on a specific body segment, provide only segmental information, discarding the complex whole-body patterns underlying the motor impairment. We aimed to assess how levodopa intake affects the whole body, large-scale kinematic network in PD.
Methods Borrowing from network theory, we used the kinectome framework by calculating the Pearson’s correlation coefficients between the time series acceleration of 21 bone markers. Then, we performed a topological analysis to evaluate the large-scale interactions between body elements. Finally, we performed a multilinear regression analysis in order to verify whether the kinectome’s topological features could predict the clinical variation before and after levodopa intake.
Results PD patients showed lower nodal strength (i.e., lower synchronization) in the upper body in the medio-lateral acceleration while in on-state with respect to the off state (p-head=0.048; p-C7=0.032; p-T10=0.006). On the contrary, PD patients in on state displayed higher nodal strength (i.e., higher synchronization) of both elbows (right, p=0.002; left, p=0.005), wrists (right, p=0.003; left, p=0.002) and knees (right, p=0.003; left, p=0.039) in the antero-posterior acceleration. Furthermore, the predictive analysis revealed that the nodal strength variations of the arms, following levodopa intake, significantly predicted the clinical variations assessed through the UPDRS-III (R2=0.65; p=0.025).
Conclusions PD patients in the on-state showed less rigidity during walking, proportional to the UPDRS-III variation. More importantly, we showed that levodopa induces an improvement of the whole body, large-scale kinematic pattern.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the European Union s Horizon 2020 research and innovation program under grant agreement No. 945539 (SGA3); Human Brain Project, Virtual Brain Cloud No. 826421 and Ministero Sviluppo Economico; Contratto di sviluppo industriale Farmaceutica e Diagnostica (CDS 000606) and European Union NextGenerationEU, (Investimento 3.1.M4. C2), project IR0000011, EBRAINS-Italy of PNRR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the local ethics committee Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli (protocol number: 0001962)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
